{"name":"Citius Pharmaceuticals","slug":"citius","ticker":"CTXR","exchange":"NASDAQ","domain":"citiuspharma.com","description":"Citius Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of critical care products. Its LYMPHIR, an FDA-approved product, is a targeted immunotherapy for the treatment of cutaneous T-cell lymphoma. The company's late-stage pipeline includes Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections; Halo-Lido, a corticosteroid-lidocaine topical formulation to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of ARDS. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.","hq":"Cranford, NJ","founded":0,"employees":"23","ceo":"Myron Holubiak","sector":"Oncology / Anti-Infective","stockPrice":0.72,"stockChange":0.07,"stockChangePercent":10.77,"marketCap":"$20M","metrics":{"revenue":3944111,"revenueGrowth":0,"grossMargin":80,"rdSpend":9156474,"netIncome":-32542912,"cash":4252290,"dividendYield":0,"peRatio":0.3,"fiscalYear":"FY2013"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Mino-Lok patent cliff ($10.0M at risk)","drug":"Mino-Lok","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Hydrocortisone acetate and lidocaine hydrochloride","genericName":"Hydrocortisone acetate and lidocaine hydrochloride","slug":"hydrocortisone-acetate-and-lidocaine-hydrochloride","indication":"Hemorrhoids (internal and external)","status":"marketed"}]}],"pipeline":[{"name":"Hydrocortisone acetate and lidocaine hydrochloride","genericName":"Hydrocortisone acetate and lidocaine hydrochloride","slug":"hydrocortisone-acetate-and-lidocaine-hydrochloride","phase":"marketed","mechanism":"Hydrocortisone acetate reduces inflammation and itching while lidocaine hydrochloride provides local anesthetic relief through topical application.","indications":["Hemorrhoids (internal and external)","Anal fissures","Pruritus ani"],"catalyst":""}],"recentEvents":[{"date":"2023-02-28","type":"earnings","headline":"Citius Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results","summary":"Citius Pharmaceuticals reported its financial results for the fourth quarter and full year 2022, with revenue of $1.4 million and a net loss of $14.1 million.","drugName":"","sentiment":"neutral"},{"date":"2022-11-14","type":"deal","headline":"Citius Pharmaceuticals Announces Exclusive Distribution Agreement with Medpace for Mino-Lok","summary":"Citius Pharmaceuticals announced an exclusive distribution agreement with Medpace for its Mino-Lok product, a treatment for catheter-related bloodstream infections.","drugName":"","sentiment":"positive"},{"date":"2022-09-01","type":"regulatory","headline":"FDA Accepts for Review Citius Pharmaceuticals' New Drug Application for Mino-Lok","summary":"The FDA accepted for review Citius Pharmaceuticals' New Drug Application for Mino-Lok, a treatment for catheter-related bloodstream infections.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxOQVdsamh3Y0w1cGtSZ0JnaGFHbDZlMjZ3T0poOTAwYXZVQmpZYURSOUo2dVB0d2J4ZDdmeklHYkZuM25YcTN5TzF1SHBud2xqcGFwcWRNWk9EUUJRWm80dXdhNGtxZTJqTFdPUVVpa2VuMk1hclBoTk1UNzZXNTVZTHJoc1loTkFhYUpuX2ozbWlnMDFOVzBaNk5IVkk3U3NXTTJTMllvbnJ6RzFtVFhlYXVIbVd1UQ?oc=5","date":"2026-04-06","type":"regulatory","source":"Stock Titan","summary":"Shareholders keep Citius (NASDAQ: CTXR) board and approve Wolf as auditor - Stock Titan","headline":"Shareholders keep Citius (NASDAQ: CTXR) board and approve Wolf as auditor","sentiment":"positive"},{"date":"2026-04-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxPMVNSWk9QT0RGRE5kbmptRWJOZDdEazFEWDVYTTNJazFZRlRrUVJaamxZX01QWTRtTGpvU3NsUE1ldThiVll0U1hub05QQ1hDTUt2U2NIQ1dUd20zUlBDazkwcEJfSEhnSFZyU214em03MVhSWFhVMTJMbElsZktUVXEydU5yUzA?oc=5","date":"2026-03-06","type":"earnings","source":"Yahoo Finance","summary":"Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR - Yahoo Finance","headline":"Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPREJaYzhPNDVBREVVOERuYVROdlkyWDFZNGFGb0dST3lNcVF0SkRpSndQX2EwX2Z5LUZJdEVuRlRURDNvVGlDM1V1SE9HazU2ajVWRVNzWXBUWWR2MzZUN1BQNXplRzZ3aXg1R0lXMTZKX183a1Zid3VrWkVFQjRpbndtNUFtWldNdWxBWnNnS0w4RTF2ZHNLOUE0WnVTQ1dGNHktX1FFVFpDc3RQaFRUZ1M0Q1hjdw?oc=5","date":"2026-03-04","type":"pipeline","source":"Stock Titan","summary":"Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results - Stock Titan","headline":"Citius Oncology (Nasdaq: CTXR) reports encouraging early LYMPHIR CAR-T combo results","sentiment":"neutral"},{"date":"2026-03-04","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxPUUVmMGtteHNOdXpZVFB4TVRmYzdTSERwZWNhZk4tek1LSEhsLVN3TXh4QTRydXdfbEt2WkN4OWV3QlZXUUM2OVQtNjBpMlR5VHJwVXU3MndPRGpBZ3ZWeUE4ZllleVA2ZXVXQjQ4d1o4TVMzWXV2MkdBYmZydFFIcFVZSkVKbUtKMUdmQ3lFVmJpY0RrSndLcmxXekg4MmpRY0hYZUYzX2JXTWdXOHRTRmw1dHlxT184RTZWaDNlSER3cGNnZVctaERld2RsakVOcWhETmhoU2NXOGtpek10TzU5a0c?oc=5","date":"2026-02-24","type":"pipeline","source":"PR Newswire","summary":"Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program - PR Newswire","headline":"Citius Pharmaceuticals, Inc. Secures $3.8 million through New Jersey Economic Development Program","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNMHBkTllWTHhJZkVVNm5VcmpraWVtSnRid0RHM1FqelBVSzJ3SGdDdVpMV0w0NmxYTE5jQ3VjU2NwY3BuMjhiSFI5RGJqbTZWMTVNU0ZOVkpNdURZQy1qYWJsdWtPd1YtaGQ4QXF3cTdKSnNlUlkxd3U1bDBkblZad1hBd2JidGFyN3pyTWFXU2xlaUJ5VnQ2OERXZW5XdGRqX2E3SXozWjVVR2ZNRTY2c2xWMjJhMUtBSEVZMU1GaGdrV0hjM0dEcVB6REVCMnByaDNnRWU1V1VIcmUzSGU1WHc5M2s5d0cxSGc?oc=5","date":"2026-02-13","type":"earnings","source":"PR Newswire","summary":"Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™ - PR Newswire","headline":"Citius Pharmaceuticals, Inc. Announces First Reported Revenue Following Successful Launch of LYMPHIR™","sentiment":"neutral"},{"date":"2026-02-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"},{"date":"2026-02-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: QUARTERLY REPORT","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-12","type":"pipeline","source":"simplywall.st","summary":"Analysts Expect Breakeven For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Before Long - simplywall.st","headline":"Analysts Expect Breakeven For Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Before Long","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi8gFBVV95cUxQaURFcnZTOVJqMThmdkR6ZFNKWFhxRFhtX3JseDBXTE8yQkdWTzdHaVcxUEI4V09PYjl4RnRERmNPY0tUYnQyTkhiTnRsYTFBTkZjblltYnhobkRvWWhvVXhseEdtRW5SNk04M3dqUjVSZ2RweUlyUkh6OVptdTVCZGEtcEN3RmtyNGc5NWJmblY3VUpKa2RDUk1QcGxkSjduRTVJWHlGOG51djNyWjE2Q25fRTJldlQwUnlxTWxjRzJzQjJfbThqREFkZjB3a0tRUEdqcjN3eG8yVW9BTy1JSmxfTlpOa3d6S19BYTdSRjdLZw?oc=5","date":"2026-02-11","type":"pipeline","source":"BioSpace","summary":"Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar - BioSpace","headline":"Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Unipha","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPZFdyamNvNXBRMk1paS1RT1RBNzJ4amZrSHM0OF9ZYXlycV9GZ201REdBQmRQWFEyVERjVmIzUFd5XzlrWVMyYU1TVllvajFkdGtPRzdXM2VWLTRTWGZoSVVlSFlRQTdqWFFucTZTWksxUjZNODdMRjdua3VQcEdSaVBicGdUVnpHbnlXamZER1VVckRWUTZvV0J0cDNkeXdkU3hfVW5WcnhLSUIzM3RNTVNxWFhWVVpzUUlnQ2xFWVZ6bGpfZEVvNFJ6TlUzcXFWQzBaeFZVQTV5VGFUOThBeU1EMUtScjVEMHc?oc=5","date":"2025-12-23","type":"earnings","source":"PR Newswire","summary":"Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update - PR Newswire","headline":"Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update","sentiment":"neutral"},{"date":"2025-12-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: CURRENT REPORT","headline":"SEC 8-K: CURRENT REPORT","sentiment":"neutral"}],"patents":[{"drugName":"Mino-Lok","drugSlug":"minocycline","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":10000000}],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Merck & Co.","Pfizer Inc.","Bayer AG"],"therapeuticFocus":["Oncology","Anti-Infective"],"financials":{"source":"sec_edgar+yahoo","revenue":0,"revenuePeriod":"2013-09-30","revenueHistory":[{"value":0,"period":"2013-09-30"},{"value":0,"period":"2012-09-30"},{"value":0,"period":"2011-09-30"},{"value":0,"period":"2010-09-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":9156474,"rdSpendHistory":[{"period":"2025-09-30","value":9156474},{"period":"2024-09-30","value":11906601},{"period":"2023-09-30","value":14819729},{"period":"2022-09-30","value":17655482}],"sgaSpend":29369134,"operatingIncome":-38525608,"operatingIncomeHistory":[{"period":"2025-09-30","value":-38525608},{"period":"2024-09-30","value":-41995681},{"period":"2023-09-30","value":-36732018},{"period":"2022-09-30","value":-33316045}],"netIncome":-32542912,"netIncomeHistory":[{"period":"2025-09-30","value":-37433911},{"period":"2024-09-30","value":-39138839},{"period":"2023-09-30","value":-32542912},{"period":"2022-09-30","value":-33640646}],"eps":-3.38,"epsHistory":[{"period":"2025-09-30","value":-3.38},{"period":"2024-09-30","value":-5.97},{"period":"2023-09-30","value":-5.57},{"period":"2022-09-30","value":-5.75}],"cash":4252290,"cashHistory":[{"period":"2025-09-30","value":4252290},{"period":"2024-09-30","value":3251880},{"period":"2023-09-30","value":26480928},{"period":"2022-09-30","value":41711690}],"totalAssets":130938025,"totalLiabilities":53410425,"totalDebt":1813273,"equity":67550178,"operatingCashflow":-26552738,"operatingCashflowHistory":[{"period":"2025-09-30","value":-26552738},{"period":"2024-09-30","value":-28201375},{"period":"2023-09-30","value":-29060212},{"period":"2022-09-30","value":-28361256}],"capex":-40006938,"capexHistory":[{"period":"2021-09-30","value":-40006938}],"freeCashflow":-26552738,"dividendsPaid":null,"buybacks":null,"employees":23,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":10000954,"ebit":-8974111,"ebitda":-8400673,"period":"2025-12-31","revenue":3944111,"epsBasic":-0.38,"netIncome":-8220785,"rdExpense":1599719,"epsDiluted":-0.38,"grossProfit":3154903,"operatingIncome":-9019208},{"sga":6795723,"ebit":-8383886,"ebitda":-8321848,"period":"2025-09-30","revenue":0,"epsBasic":null,"netIncome":-7959288,"rdExpense":1641586,"epsDiluted":null,"grossProfit":null,"operatingIncome":-8437309},{"sga":7166682,"ebit":-8767370,"ebitda":-8726003,"period":"2025-06-30","revenue":0,"epsBasic":-0.8,"netIncome":-8789872,"rdExpense":1621325,"epsDiluted":-0.8,"grossProfit":null,"operatingIncome":-8788007},{"sga":7494153,"ebit":-11260678,"ebitda":-11204668,"period":"2025-03-31","revenue":0,"epsBasic":-1.27,"netIncome":-10916505,"rdExpense":3766525,"epsDiluted":-1.27,"grossProfit":null,"operatingIncome":-11260678},{"sga":7912576,"ebit":-10017006,"ebitda":-9962171,"period":"2024-12-31","revenue":0,"epsBasic":-1.3,"netIncome":-9768246,"rdExpense":2127038,"epsDiluted":-1.3,"grossProfit":0,"operatingIncome":-10039614},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.72,"previousClose":0.65,"fiftyTwoWeekHigh":2.48,"fiftyTwoWeekLow":0.57,"fiftyTwoWeekRange":"0.57 - 2.48","fiftyDayAverage":0.79,"twoHundredDayAverage":1.04,"beta":1.05,"enterpriseValue":22162738,"forwardPE":0.3,"priceToBook":0.2,"priceToSales":4.98,"enterpriseToRevenue":5.62,"enterpriseToEbitda":-0.61,"pegRatio":0,"ebitda":-36357252,"ebitdaMargin":0,"freeCashflow":-40525064,"operatingCashflow":-34835708,"totalDebt":1829646,"debtToEquity":2,"currentRatio":0.99,"returnOnAssets":-17.7,"returnOnEquity":-47.9,"analystRating":"","recommendationKey":"none","numberOfAnalysts":1,"targetMeanPrice":6,"targetHighPrice":6,"targetLowPrice":6,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":1.8,"institutionHeldPercent":6.6,"sharesOutstanding":27452570,"floatShares":21969624,"sharesShort":5263532,"shortRatio":6.33,"shortPercentOfFloat":19.2,"epsTrailing":-2.46,"epsForward":2.79,"revenuePerShare":0.27,"bookValue":3.57,"officers":[{"age":80,"name":"Mr. Leonard L. Mazur","title":"Co-Founder, CEO, Chairman & Secretary"},{"age":78,"name":"Mr. Myron Z. Holubiak","title":"Co-Founder & Executive Vice Chairman"},{"age":65,"name":"Dr. Myron S. Czuczman M.D.","title":"Executive VP & Chief Medical Officer"},{"age":57,"name":"Mr. Jaime  Bartushak","title":"Chief Business Officer & CFO"},{"age":70,"name":"Mr. Gary F. Talarico","title":"Executive Vice President of Operations"},{"age":null,"name":"Ms. Ilanit  Allen","title":"Vice President of Investor Relations & Corporate Communications"},{"age":null,"name":"Dr. Alan  Lader Ph.D.","title":"Senior VP and Head of Clinical Operations & Quality Assurance"},{"age":71,"name":"Mr. Dhananjay G. Wadekar","title":"Senior Vice President of Business Strategy"}],"industry":"Biotechnology","irWebsite":"","website":"https://citiuspharma.com","phone":"908 967 6677"}}